Gravel TechnologyTranslation site

ReviR Therapeutics (ReviR) is a company that specializes in artificial intelligence algorithms andbiotechnologydriven innovative drug discovery company focused on leveraging AI technology and RNA research together to drive innovative drug discovery and development to address long unmet clinical needs in areas such as oncology, infections and rare diseases.

Company Overview

• Date and place of establishmentFounded in Silicon Valley in 2021, Creek Gravel Technology has a major operational base in Shenzhen, China, located at A3802, Building 11, Shenzhen Bay Science and Technology Eco-Park, No. 16 South Science and Technology Road, High-Tech Zone Community, Yuehai Street, Nanshan District, Shenzhen, China.
• registered capital: The registered capital of the Company is RMB 30 million.
• Type of company: Science and technology-based small and medium-sized enterprises
• Scope of business: cloud computing equipment technology services, software development, medical research and experimental development (except for human stem cells, gene diagnosis and treatment technology development and application), technical services for software and biology, technology development, technology consulting, technology transfer, technology promotion, retailing of computer software, hardware and software and auxiliary equipment, sales of experimental and analytical instruments, sales of first-class medical equipment, health consulting services (excluding diagnostic and therapeutic services), and so on.

Core Technology and Products

• VoyageR AI Platform: Stream Gravel Technology focuses on spatial structure calculation of RNA targets and development of potential drug candidates by building the VoyageR AI platform. The platform is able to subvert the traditional pharmaceutical process in terms of speed, efficiency, and cost, and rapidly obtain preclinical candidate compounds through a wet/dry closed loop of high-throughput screening + AI + automated experimental validation.
• Small molecule drugs targeting RNAThe company is committed to challenging "non-druggable" targets and developing small molecule drugs that target RNA to drive related breakthrough therapeutic research.

Team Members

• Dr. Li YangCo-founder and Chairman of Creek Gravel Technology, Dr. Xu graduated from University of Illinois with a PhD degree. During his PhD, he invented a series of patented algorithms around RNA regulation, such as TrueSight, etc. He has been working on AI algorithms and bioinformatics.
• Dr. Yue PengCo-founder and CEO of Creek Gravel Technology, he has worked in large pharmaceutical companies such as Genentech, Gilead, AbbVie, 23andMe, etc., and served as the head of bioinformatics R&D for a long time, and has nearly 20 years of experience in the pharmaceutical field, especially in the direction of utilizing big data for target discovery and assisting in the R&D of new drugs.
• Other members: The company's core team also includes Dr. Paul August, Chief Scientist, Prof. Lynne E. Maquat, member of the Scientific Advisory Board, and Dr. Sridhar Narayan, Vice President of Chemistry, with a strong background of team members who have provided a solid force for the company's rapid growth.

Financing

• Series A financing: On July 26, 2024, Creek Gravel Technology completed $30 million in Series A financing, with investors including Yayi Capital, CMT Research Foundation, CDH Investment, Jintai Technology, Wuyuan Capital, and Longpan Investment. The amount of this round of financing ranks in the top 20% of all Series A financing this year, providing strong financial support for the company's subsequent R&D and pipeline advancement.

Cooperation and development

• Cooperation CasesOn Feb. 8, 2023, CreekGravel announced a collaboration with Asiahong Pharmaceuticals to develop innovative drugs around two genitourinary tumor targets based on the VoyageR AI drug discovery and development platform and targeted RNA technology. This cooperation reflects the market's recognition and optimism of Creek Gravel's technological strength.
• future outlookXigong Technology will continue to focus on the field of oncology and rare diseases, and promote the steady development of multiple R&D pipelines. Meanwhile, the company will also continue to explore more application scenarios of AI in drug development, with a view to making more breakthroughs in the field of innovative drug development.

To summarize, with its strong technical strength, excellent team background and sufficient financial support, Xigong Technology is becoming a leader in the field of AI-driven small molecule targeted RNA innovative drug discovery and development.